Program
eratrectinib
Also written as “VC004 Capsules”, “VC004 low dose” and “VC004 high dose”.
Its studies are mostly in Neoplasm Metastasis, led by Jiangsu vcare pharmaceutical technology.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu vcare pharmaceutical technology | 62 open or running | phase 3since Oct 24, 2024 | Oct 12, 2020 | Dec 30, 2026phase 3 · NCT06658353 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 12, 2020First study: phase 2 study in Neoplasm MetastasisFirst studyNCT04614740 · 115 enrolled · China
- Sep 1, 2022Phase 1 study in Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene FusionNCT05528120 · 16 enrolled · China
- Jul 26, 2024Phase 1 study in Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene FusionNCT06529445 · 84 enrolled · China
- Sep 28, 2024Phase 1 study in Neoplasm MetastasisNCT06619951 · 56 enrolled · China
- Oct 24, 2024Phase 3 study in Locally Advanced Solid TumorNCT06658353 · 54 planned · China
- Jul 23, 2026Phase 1 study in Pain in Bone MetastasesNCT07731685 · 26 planned · China
Ahead
- Dec 30, 2026Primary completion: phase 3 study in Locally Advanced Solid TumorNCT06658353
- Dec 30, 2027Primary completion: phase 1 study in Pain in Bone MetastasesNCT07731685
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07731685Pain in Bone Metastases · China | 1 | Not yet recruiting | Dec 30, 2027 | 26 |
| NCT06658353Locally Advanced Solid Tumor · China | 3 | Recruiting | Dec 30, 2026 | 54 |
| NCT06619951Neoplasm Metastasis · China | 1 | Completed | Oct 31, 2024 | 56 |
| NCT06529445Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion · China | 1 | Completed | Aug 26, 2024 | 84 |
| NCT05528120Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion · China | 1 | Completed | Oct 28, 2022 | 16 |
| NCT04614740Neoplasm Metastasis · China | 2 | UNKNOWN | Jan 31, 2024 | 115 |
How it is read
Names in the registry
- “VC004 Capsules”, 3 entries
- “VC004 low dose”, 1 entry
- “VC004 high dose”, 1 entry
- “VC004 and Itraconazole”, 1 entry
- “VC004 and rifampicin”, 1 entry
Codes read as this program: VC004.
Conditions, from the studies’ own filings
- Neoplasm Metastasis, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.